Summary: The UK’s Maxwellia has been on quite a journey, from “switch-in-a-box” start-up to a consumer healthcare company in its own right, launching some of the most innovative products on the way. Specialising so far in women’s health, with OTC brands ranging from the first-in-class daily contraceptive pill to much needed menstrual health solutions, Maxwellia CEO Anna Maxwell now has her eye on a recently published list of Rx-to-OTC switched the UK government would like to see applications for. To realise these switches, Maxwell calls for the government to make it easier for smaller companies like Maxwellia to access all important funding. Timeline 2:00 – Introductions 3:00 – Maxwellia’s growth journey 11:00 – Innovating in women’s health 20:00 – Room for growth in the women’s health category 21:00 – UK government’s Rx-to-OTC switch wishlist 25:00 – The advantages of being a small company 27:00 – Beyond women’s health 30:00 – The disadvantages of being a large company 31:20 – Maxwellia’s immediate future Guest Bio Anna Maxwell is a pioneering pharmacist and healthcare entrepreneur reshaping public health by making essential medicines more accessible. As founder and CEO of Maxwellia, she’s driving growth with strong retail partnerships, a robust innovation pipeline, and plans for international expansion. With a clear vision and relentless drive for innovation, Maxwell is leading a movement to give people more control over their health – “because the future of self-care is here, and Maxwellia is making it happen.”

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related